Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have relapsed or treatment-resistant multiple myeloma and have already tried at least 3 lines of treatment, with no remaining standard treatment options expected to provide meaningful benefit (or who are not suitable candidates for those options)
- People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (confirm with trial site)
- People whose multiple myeloma can be measured and tracked through specific tests described in the trial protocol
- People whose blood counts, heart, liver, and kidneys are functioning at adequate levels as defined by the trial protocol
Who may not be able to join:
- People who have certain specific forms or complications of the disease, including non-secretory multiple myeloma, active plasma cell leukemia, amyloidosis, Waldenström macroglobulinemia, or POEMS syndrome
- People who have multiple myeloma that has spread to the brain or central nervous system
- People who have a history of a rare brain infection called PML, a condition affecting thinking or memory, a movement disorder affecting the nervous system, or a seizure within the 12 months before entering the trial screening process
- People who have previously been treated with certain targeted therapies directed at a protein called GPRC5D, or (for one part of the trial) with a specific type of therapy called a BCMAxCD3 bispecific antibody
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab; Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamab; Severity of TEAEs associated with REGN17372 in combination with linvoseltamab; Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugs; VGPR or better as determined by the investigator using the IMWG response criteria in patients...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.